Azilsartan kaMedoxoMil

Base Information

• Chemical Name: Azilsartan kaMedoxoMil
• CAS No.: 863031-24-7
• Molecular Formula: C30H24N4O8.K
• Molecular Weight: 607.63200
• Mol file: 863031-24-7.mol

Synonyms:potassium,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-(5-oxo-1-oxa-2-aza-4-azanidacyclopent-2-en-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate; Azilsartan kamedoxomil; TAK-491; WEC6I2K1FC; Azilsartan medoxomil monopotassium; Azilsartan kamedoxomil (USAN); UNII-WEC6I2K1FC; 查看更多英文别名 收起

Chemical Property of Azilsartan kaMedoxoMil

Chemical Property:

• Appearance/Colour: White or offwhite powder
• PSA: 152.69000
• LogP: 4.33430
• Storage Temp.: Refrigerator, Under inert atmosphere
• Solubility.: DMSO (Slightly), Methanol (Slightly)

Purity/Quality:

99% ^*data from raw suppliers

Azilsartan medoxomil potassium ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Uses: Azilsartan Kamedoxomil is an angiotensin II receptor blocker.
• Clinical Use: Azilsartan kamedoxomil, developed by Takeda Pharmaceuticals, was approved for the treatment of hypertension and launched in the U.S. under the brand name Edarbi. Edarbi is a prodrug that undergoes rapid hydrolysis to liberate azilsartan, the active ingredient (TAK-536, 39). As the 8th angiotensin receptor blocker (ARB) to enter the world market, azilsartan kamedoxomil can function as monotherapy or in combination with other antihypertensive agents. In several clinical studies, monotherapeutic azilsartan kamedoxomil showed superior antihypertensive activity and a favorable safety/tolerability profile in patients compared with other established therapeutics, including valsartan, olmesartan medoxomil, candesartan, and telmisartan.In late 2011,Takeda announced that FDA also approved the fixed-dose combination tablet of azilsartan kamedoxomil with chlorthalidone under the trade name of Edarbyclor.